Joint meeting of the International Society for STD, Research (22nd meeting) and IUSTI (18th World Congress), Rio de Janeiro, Brazil, 9–12 July 2017

WHO PARTICIPATION IN THE PROGRAMME
Sunday 9 July 2017

8.00 – 12.00, Room Alvorada I

**STI guidelines and STI estimates**

The session will provide an update of the new WHO treatment guidelines on *Neisseria gonorrhoea*, *Chlamydia trachomatis*, *Treponema pallidum* and genital herpes simplex virus and the new syphilis screening and treatment guidelines among pregnant women. The evidence which were the basis for these guidelines as well as practical issues in implemtation will also be highlighted. The roadmap for the development of new treatment for gonorrhoea will also be discussed. An overview of the WHO guideline development process will be discussed as well as emerging issues that need to be addressed related to treatment guideline development.

The session will also orient the participants on the current STI surveillance strategies and initiatives and provide an overview on the current methods and tools on estimating STIs and congenital syphilis.

**WHO focal points:** Teodora Wi (wit@who.int), Melanie Taylor (mtaylor@who.int)

13.00 – 17.00, Room Alvorada I

**Resourcing ambitious 2020 and 2030 targets for sexually transmitted infections**

The round table will review the human and population cost of STIs, update participants on current STI policy frameworks, identify possible sources of financing and discuss barriers and opportunities to financing the Global STI strategy. There will be also the launch of PLOS Collection and Call for Papers on accelerating action on sexually transmitted infections.

**WHO focal points:** Nathalie Broutet (broutetn@who.int), Massimo Ghidinelli (ghidinellim@paho.org), Antonio Gerbase (gerbasea@gmail.com)

9:00 – 13.30, Room Liberdade

**HIV research perspectives in Latin American women**

This session has a particular focus on women and girls and has the overall objective to provide an overview of the current situation on the STI and HIV epidemics in Latin America and identifying research priorities and challenges to advance the health agenda for this population.

**WHO focal points:** Suzanne Serruya (serruyas@paho.org), Manjulaa Narasimhan (narasimhanm@who.int)
Monday 10 July 2017

**11.15 - 12.30, Symposium 3, Room 3, Alhambra II**

**Latest generation point-of-care tests for STIs/HIV – a marriage of innovation and technology**

**Chairs:** Francis Ndowa & Arlene Sena-Soberano  
**WHO focal point:** Igor Toskin (toskini@who.int)

**14.00 – 15.30, Symposium 5, Room 2, Alhambra I**

**Progress on STI vaccines**

**Chair:** Carolyn Deal, NIH

Development of new vaccines against STIs remains an important goal for global sexual and reproductive health. This session will discuss global efforts to advance STI vaccine development, progress in development of vaccines against Neisseria gonorrhoea, herpes simplex virus, Chlamydia trachomatis, and Treponema pallidum, and important next steps in implementing the global STI vaccine roadmap.

**WHO focal point:** Sami Gottlieb (gottliebs@who.int)

**14.00 – 15.30, Symposium 6, Room 3, Alhambra II**

**Policy gaps and opportunities in the elimination of congenital syphilis**

Achievements and updates in global guidance for EMTCT validation; Towards triple elimination of mother to child transmission of HIV, syphilis and hepatitis B; Asia Pacific regional framework for triple elimination of mother-to-child transmission of HIV, syphilis and hepatitis B – opportunities for synergies, Shortages of benzathine penicillin: identifying opportunities to ensure stable and adequate supply, Role of rapid tests in the elimination of congenital syphilis.

**WHO focal points:** Melanie Taylor (mtaylor@who.int), Massimo Ghinelli (ghinelli@paho.org), Naoko Ishikawa (ishikawa@wpro.who.int)

**19.00 – 20.30, WHO-CDC-NIH Session, Room 1, Segóvia I, II, & III**

**Emergence of new STI: facts and challenges**

Review of sexual transmission of Ebola and Zika virus and impact on the epidemics; How to explore sexual transmission? A sexual transmission framework; A study in Brazil; Summary of sexual transmission of Ebola; Health messaging and communication; Considerations for implementation of sexual transmission.

**WHO focal point:** Nathalie Broutet (broutetn@who.int)
Tuesday 11 July 2017

11.15 – 12.30, Symposium 8, Room 2, Alhambra I
Investigating the importance of integrated interventions to advance the sexual and reproductive health of women and girls at risk of STIs, including HIV

Investigating combination SRH/HIV interventions and the importance of addressing integrated approaches to advance SRHR in STI and HIV prevention for adolescent girls and young women and SRHR of women living with HIV.

**WHO focal point:** Manjulaa Narasimhan (narasimhanm@who.int)

14.00 – 15.30, Symposium 10, Room 1, Segóvia I, II, & III
Tackling antimicrobial resistance in *Neisseria gonorrhoeae*: a need for a comprehensive and collaborative approach

This symposium will discuss the current responses and future directions to prevent and mitigate antimicrobial resistance in *N. gonorrhoeae* through comprehensive and collaborative approaches. The symposium will highlight AMR in *N. gonorrhoeae* in Latin America and the Caribbean emphasizing available data, challenges and opportunities. An essential component to reduce AMR in gonorrhoea, include the need for appropriate treatment and its rationale use, new treatments and the potential for a gonorrhoea vaccine. Laboratory diagnosis is essential for gonorrhoea AMR monitoring as well as for appropriate diagnosis and control measures. New technologies, including the role of point of care test and molecular AMR testing will be explained in the context of low and middle income countries.

**WHO focal point:** Teodora Wi (wit@who.int), Massimo Ghidinelli (ghidinellim@paho.org)

Wednesday 12 July 2017

08.45 – 09.15, Plenary 11, Room 1, Segóvia I, II, & III
To Be or not to Be, Civil society and HIV: Why not the other STIs? by Fabio Mesquita

**WHO focal point:** Fabio Mesquita (mesquitaf@who.int)

13.30 – 15.00, Symposium 16, Room 2, Alhambra I
Pre-Exposure Prophylaxis (PrEP) of HIV: impact on sexually transmitted infections (STIs) and lessons learned from real-life implementation.


**WHO focal points:** Ioannis Hodges-Mameletzis (mameletzisi@who.int), Giovanni Ravasi (ravasigi@paho.org)